| Bioactivity | Revusiran (ALN-TTRSC) is a 1st-generation short interfering RNA, which directed against transthyretin (TTR) mRNA. Revusiran can be used for transthyretin (TTR)-mediated amyloidosis research[1]. |
| Invitro | Revusiran is a chemically synthesized double-stranded siRNA that is covalently linked at the 3′-end of its sense strand to a ligand containing three GalNAc residues. Revusiran is a 1st-generation short interfering RNA targeting transthyretin conjugated to an N-acetylgalactosamine ligand to facilitate delivery to hepatocytes via uptake by the asialoglycoprotein receptors[1]. |
| In Vivo | There are no effects on cardiovascular or respiratory function in monkeys after single doses of up to 100 mg/kg. No neurological effects weare noted in monkeys in repeat-dose studies up to 300 mg/kg. Revusiran is well tolerated in repeat-dose mouse (weekly doses) and rat and monkey (five daily doses followed by weekly doses) toxicity studies[1]. |
| Name | Revusiran |
| CAS | 1438322-82-7 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jessica E Sutherland, et al. Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis. Nucleic Acid Ther. 2020 Feb;30(1):33-49. |